Spyre Therapeutics (FRA:3920) FCF Margin %: 0.00% (As of Mar. 2026)


FRA:3920 Spyre Therapeutics Inc FRA:3920
33 GF Score
Price €77.00
! 4 Warning Signs
View Full Analysis

What is Spyre Therapeutics FCF Margin %?

Spyre Therapeutics FRA:3920 +0.65% 33 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:3920 with a GF Score™ of 33/100. The stock has 4 warning signs investors should review. Among 959 Biotechnology companies, Spyre Therapeutics ranks worse than 104275.18% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Spyre Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was €-49.63 Mil. Spyre Therapeutics's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Spyre Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Spyre Therapeutics's current FCF Yield % is -2.44%.

The historical rank and industry rank for Spyre Therapeutics's FCF Margin % or its related term are showing as below:


During the past 13 years, the highest FCF Margin % of Spyre Therapeutics was -289.71%. The lowest was -11276.52%. And the median was -661.83%.

FRA:3920's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -84.65
* Ranked among companies with meaningful FCF Margin % only.

Spyre Therapeutics FCF Margin % Related Terms

Spyre Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Spyre Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spyre Therapeutics FCF Margin % Chart

Spyre Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -289.71 -3,442.11 -11,282.88 0.00 0.00

Spyre Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:3920 vs PTGX, CELC, MIRM: FCF Margin % Comparison

For the Biotechnology subindustry, Spyre Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spyre Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Spyre Therapeutics's FCF Margin % falls into.


FRA:3920
33GF Score
Spyre Therapeutics Inc FRA:3920
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spyre Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Spyre Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-144.541/0
= %

Spyre Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-49.627/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Spyre Therapeutics (FRA:3920) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Spyre Therapeutics and its competitors. According to the industry distribution chart, Spyre Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry.
Is Spyre Therapeutics' FCF Margin % too high?
Spyre Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, Spyre Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Spyre Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Spyre Therapeutics' FCF Margin % compare to PTGX and CELC?
According to the Biotechnology industry distribution chart, Spyre Therapeutics ranks #999999 out of 959 companies for FCF Margin %. This places Spyre Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Spyre Therapeutics and its competitors. Spyre Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spyre Therapeutics stock overvalued right now?
Spyre Therapeutics (FRA:3920) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Spyre Therapeutics' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Spyre Therapeutics (FRA:3920), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Spyre Therapeutics Business Description

Other Exchanges SYRE:USA3920:Germany
Address 221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
33GF Score

Get the complete analysis for FRA:3920

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€77.00
Price